Veracyte is a genomic diagnostics company that uses advanced genomic technology to resolve diagnostic uncertainty and deliver actionable results that improve patient care and outcomes. The company's tests in thyroid, lung, and breast cancer, and in idiopathic pulmonary fibrosis, are becoming standard of care in helping patients avoid unnecessary invasive procedures, while resolving inconclusive results from traditional diagnostic methods. Veracyte's genomic tests are covered by Medicare and many commercial insurance plans. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. The company was founded in 2008 and is headquartered in South San Francisco, California.